ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs
September 27, 2018WuXi Biologics and I-Mab Biopharma jointly announce today that I-Mab has expanded strategic collaboration with WuXi Biologics and licensed proprietary WuXiBody™ Platform to develop three bispecific antibodies. -
I-Mab Biopharma, MorphoSys declares China IND Submission of monoclonal antibody
August 10, 2018The company has Submitted an investigational new drug (IND) application to China National Drug Administration (CNDA) for TJ202/MOR202, a human monoclonal antibody directed against CD38 for the treatment of multiple myeloma. -
I-Mab Biopharma, ABL Bio collaborate for innovative bispecific Abs
July 30, 2018Under the terms of the agreement, ABL Bio will pay $2.5 million in upfront payment.
Pharma Sources Insight January 2025
